New Sensor Helps Sleep Disorder Patients

New trial testing on a mattress sensor that can help people with their individual sleep disorders is conducted by Flinders University sleep experts.

The sleep disorder diagnosis and monitoring trial will be conducted using invisible sensor technology, REMi developed by RMIT University for Melbourne-based R&D company Sleeptite to investigate its capacity as a validation tool for sleep disorders.

Polysomnography | Sleep Study
Polysomnography (PSG) or sleep study is a test done to diagnose sleep disorders by recording brain waves and sleep patterns. PSG can also be useful to monitor response to treatment of sleep disorders and adjust treatment plan suitably.

‘Sleeptite REMi sensors in mattress will improve sleep quality in sleep disorder patients.’

Tweet it Now

“Sleep, exercise and healthy eating are essential for a healthy life, and missing out on sleep – including with an untreated sleep disorder – can have serious long and short-term health consequences”, says, Associate Professor Vakulin

This research validated sleep measurement metrics and algorithms using the REMi sensors, and to further enhance their capability to provide informative data.

Sleeptite REMi sensors in mattress give a reliable measure of sleep quality, and sleep disorders will ultimately lead to new apps that help consumers to improve their sleep health.

Cognitive Behavioral Therapy for Insomnia
Cognitive behavioral therapy can reduce insomnia symptoms and also reduce symptoms of anxiety, depression and stress.

The Sleep Health Foundation and Deloitte show that 1 in 10 Australians suffer from a sleep disorder, which increased the need for research in this space at a national economic cost of $14.4 billion.

The flexible and stretchable sensors developed at RMIT makes REMi a unique technology that is nearable and unfeelable will enable sleep studies to be carried out in far more natural settings.

Snoring in Children Linked to Brain Changes
Children who snore with loud noise at least three nights per week are more likely to developbehavioral problems and learning disabilities.

The REMi Sleep Diagnosis Evaluation Trial will involve 30 participants and will be evaluated against polysomnography (PSG) results.

The REMi Sleep Diagnosis Evaluation Trial at Flinders is expected to last six months and include further sensor capability testing of the REMi sensors and identifying key sleep-related parameters.

Long-term Opioid Use Ups the Risk of Sleep Disorders
New statement by American academy of sleep medicine increases awareness among health care providers of the important adverse events that can occur in patients on chronic opioid therapy.

The trial will develop an algorithm that will recognize sleep quality by establishing relationships between sensor signals and sleep measurements.

The researchers are looking forward to discovering new avenues of partnership for this platform technology, and the opportunity to build deep collaborations to take this world-first system beyond aged care.

Source-Medindia